fda approval of tirzepatide for weight loss Grants a New Indication Obesity Management Tirzepatide is FDA-approved for weight

Unveiling tirzepatide's therapeutic spectrum: A dual GIP/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health

DAMPs also impact Kupffer cells, activating the nucleotide-binding oligomerization domain-like receptor (NLR) Family, Pyrin Domain-Containing 3 protein (NLRP3), a type of inflammasome leading to IL-1 secretion and inflammation, and pyroptosis, releasing more DAMPs and perpetuating a destructive cycle (Hammerich and Tacke, 2023)

Researchers have studied how AOD-9604 interacts with beta-adrenergic receptors in metabolic models, examining its selectivity profile compared to native growth hormone fragments

Every time I open Instagram, it seems to only take a few seconds of scrolling for me to be served a post for a GLP-1 medication like Ozempic, Wegovy, or Zepbound

No subscription or membership required

A pilot clinical study by Sasaninia et al